Blood Transfusion for Thalassemia: Indications, Protocols, and Complications
Thalassemia syndromes (α/β) cause ineffective erythropoiesis and hemolytic anemia. Transfusion is life-sustaining for transfusion-dependent thalassemia (TDT).
Transfusion Goals
- Maintain pre-transfusion Hb 9–10.5 g/dL (TDT); higher if cardiac disease.
- Suppress endogenous erythropoiesis (prevents extramedullary hematopoiesis, bone deformities).
- Interval: every 2–4 weeks (adjusted to Hb drift).
Blood Product Specifications
- Leukoreduced (pre-storage) → reduces alloimmunization, CMV, febrile reactions.
- Phenotype-matched (Rh, Kell, Duffy, Kidd) → delays alloimmunization.
- Irradiated (25 Gy) → prevents TA-GVHD (if HLA risk).
- Washed if severe allergic reactions.
Complications
- Iron overload: Inevitable (1 unit = 200–250 mg Fe). Requires chelation (deferasirox, deferiprone, deferoxamine). Monitor ferritin, MRI T2* (heart/liver).
- Alloimmunization: 10–30% despite matching; complicates future transfusion.
- Infections: Residual risk (HBV, HCV, HIV <1/1M; bacterial sepsis rare).
- Transfusion reactions: Febrile non-hemolytic, allergic, TRALI, TACO, DHTR.
Curative Option
Allogeneic HSCT (matched sibling best) or gene therapy (betibeglogene autotemcel for β-thalassemia).
Comprehensive care (hematology, cardiology, endocrinology, psychology) enables near-normal lifespan.
Blood Disorders - Related Articles
- Understanding Blood Color: Why Deoxygenated Blood Is Darker
- Vitamin K Dependent Factors: Understanding Blood Clotting & Deficiency
- Platelets (Thrombocytes): Functions in Hemostasis & Beyond
- Can Someone with Type O Blood Have Children with Different Blood Types?
- Blood Solutions: Understanding Heterogeneous Mixtures
- Thalassemia Treatments: Understanding Options & Management
- Menstrual Blood Clots: Normal Size and When to Be Concerned
